Fmoc-L-Gly(adamantyl)-OH

Chemischer Name: N-alpha-(9-Fluorenylmethyloxycarbonyl)-1-adamantyl-L-glycine // Synonyme: Fmoc-Gly(1-adamantyl)-OH, (S)-Fmoc-1-adamantyl-glycine, (S)-2-{[(9-fluorenyl)methyloxycarbonyl]amino)-2-(adamantan-1-yl)acetic acid, Fmoc-Gly(adamantyl)-OH

Art-Nr.:FAA4180
CAS Nr.:1221793-29-8
Lagertemperatur:2-8°C
Formel:C₂₇H₂₉NO₄
Molare Masse:431,52 g/mol

Ab 135,00 €

Gruppiert Produkte - Artikel
Verpackungsgröße	Preis	SKU	Warenverfügbarkeit
250 mg	135,00 €	FAA4180.0250	<10 Arbeitstage
1 g	400,00 €	FAA4180.0001	<10 Arbeitstage
5 g	1.600,00 €	FAA4180.0005	<10 Arbeitstage

Skip to the end of the images gallery

Skip to the beginning of the images gallery

description

Building block of choice, whenever a bulky, hydrophobic residue is required.

references

Tumor-Cell-Targeted Methionine-enkephalin Analogues Containing Unnatural Amino Acids: Design, Synthesis, and in Vitro Antitumor Activity; S. Horvat, K. Mlinariæ-Majerski, L. Glavaš-Obrovac, A. Jakas, J. Veljkoviæ, S. Marczi, G. Kragol, M. Rošèiæ, M. Matkoviæ, A. Milostiæ-Srb; J. Med. Chem. 2006; 49(11): 3136-3142. https://doi.org/10.1021/jm051026+.

An Adamantyl Amino Acid Containing Gramicidin S Analogue with Broad Spectrum Antibacterial Activity and Reduced Hemolytic Activity; V. V. Kapoerchan, A. D. Knijnenburg, M. Niamat, E. Spalburg, A. J. de Neeling, P. H. Nibbering, R. H. Mars-Groenendijk, D. Noort, J. M. Otero, A. L. Llamas-Saiz, M. J. van Raaij, G. A. van der Marel, H. S. Overkleeft, M. Overhand; Chem. Eur. J. 2010; 16(40): 12174-12181. https://doi.org/10.1002/chem.201001686.

Tuning hydrophobicity of highly cationic tetradecameric Gramicidin S analogues using adamantane amino acids; A. D. Knijnenburg, V. V. Kapoerchan, E. Spalburg, A. J. de Neeling, R. H. Mars-Groenendijk, D. Noort, G. A. van der Marel, H. S. Overkleeft, M. Overhand; Bioorg. Med. Chem. 2010; 18(23): 8403-8409. https://doi.org/10.1016/j.bmc.2010.09.018.

‘Inverted’ analogs of the antibiotic gramicidin S with an improved biological profile; V. V. Kapoerchan, A. D. Knijnenburg, P. Keizer, E. Spalburg, A. J. de Neeling, R. H. Mars-Groenendijk, D. Noort, J. M. Otero, A. L. Llamas-Saiz, M. J. van Raaij, G. A. van der Marel, H. S. Overkleeft, M. Overhand; Bioorg. Med. Chem. 2012; 20(20): 6059-6062. https://doi.org/10.1016/j.bmc.2012.08.038.

Structure-activity relationship study of the tumour-targeting peptide A20FMDV2 via modification of Lys16, Leu13, and N- and/or C-terminal functionality; K.-Y. Hung, P. W. R. Harris, A. Desai, J. F. Marshall, M. A. Brimble; Eur. J. Med. Chem. 2017; 136: 154-164 . https://doi.org/10.1016/j.ejmech.2017.05.008.

Structure-Based Design of Non-natural Macrocyclic Peptides That Inhibit Protein-Protein Interactions; D. M. Krüger, A. Glas, D. Bier, N. Pospiech, K. Wallraven, L. Dietrich, C. Ottmann, O. Koch, S. Hennig, T. N. Grossmann; J. Med. Chem. 2017; 60(21): 8982-8988. https://doi.org/10.1021/acs.jmedchem.7b01221.

J. Müller, R. A. Kirschner, J.-P. Berndt, T. Wulsdorf, A. Metz, R. Hrdina, P. R. Schreiner, A. Geyer, G. Klebe; ChemMedChem 2019; 14: 663-672. https://doi.org/10.1002/cmdc.201800779.